REPLIMUNE GROUP INC's ticker is REPL and the CUSIP is 76029N106. A total of 106 filers reported holding REPLIMUNE GROUP INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4,228,617 | -6.1% | 182,111 | -28.6% | 0.01% | -15.4% |
| Q1 2023 | $4,501,958 | +207.9% | 254,924 | +201.2% | 0.01% | +160.0% |
| Q3 2022 | $1,462,000 | +39.0% | 84,634 | +40.6% | 0.01% | +66.7% |
| Q2 2022 | $1,052,000 | -71.7% | 60,207 | -72.5% | 0.00% | -72.7% |
| Q1 2022 | $3,715,000 | +41.7% | 218,792 | +126.2% | 0.01% | +83.3% |
| Q4 2021 | $2,621,000 | -16.7% | 96,708 | -8.9% | 0.01% | -14.3% |
| Q3 2021 | $3,146,000 | -47.8% | 106,156 | -32.3% | 0.01% | -50.0% |
| Q2 2021 | $6,028,000 | -46.4% | 156,888 | -57.4% | 0.01% | -51.7% |
| Q1 2021 | $11,249,000 | -10.4% | 368,695 | +12.1% | 0.03% | -19.4% |
| Q4 2020 | $12,549,000 | +754.3% | 328,932 | +415.3% | 0.04% | +620.0% |
| Q3 2020 | $1,469,000 | +360.5% | 63,835 | +397.7% | 0.01% | +150.0% |
| Q2 2020 | $319,000 | -35.3% | 12,827 | -62.6% | 0.00% | +100.0% |
| Q4 2019 | $493,000 | – | 34,332 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 3,050,187 | $53,866,302 | 35.13% |
| Atlas Venture Life Science Advisors, LLC | 2,098,300 | $37,055,978 | 5.02% |
| Redmile Group, LLC | 3,811,988 | $67,319,708 | 2.92% |
| Nan Fung Group Holdings Ltd | 189,339 | $3,343,727 | 2.28% |
| Altium Capital Management LP | 148,000 | $2,613,680 | 1.45% |
| Integral Health Asset Management, LLC | 395,000 | $6,975,700 | 1.40% |
| BVF INC/IL | 2,143,036 | $37,846,016 | 1.38% |
| Resolute Capital Asset Partners LLC | 82,500 | $1,457 | 1.06% |
| SECTORAL ASSET MANAGEMENT INC | 262,200 | $4,630,452 | 0.89% |
| Frazier Life Sciences Management, L.P. | 686,762 | $12,128,217 | 0.88% |